AI assistant
BIOGEN INC. — Director's Dealing 2018
Apr 27, 2018
30291_dirs_2018-04-27_c56dd69e-1196-4c25-a869-3eb5954dfe89.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2018-04-25
Reporting Person: DENNER ALEXANDER J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-04-25 | Common Stock | P | 48000 | $269.91 | Acquired | 461858 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 10029 | Direct |
Footnotes
F1: On April 25, 2018, funds managed by Sarissa Capital Management LP (such funds, the "Sarissa Funds") purchased an aggregate of 48,000 shares of common stock of Biogen Inc. All of the shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by the Sarissa Funds.
F2: Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.